Seasonal Depression (SAD): More Than Just the Winter Blues

Seasonal affective disorder does not appear in the DSM-5 as a standalone diagnosis. It is instead a specifier — “with seasonal pattern” — applied to recurrent major depressive disorder or bipolar disorder. The criteria require that depressive episodes have occurred in the same season for at least two consecutive years, that remissions (or switches to mania/hypomania in bipolar) also occur seasonally, and that the seasonal episodes substantially outnumber any nonseasonal episodes the person has had.

Why does this matter clinically? Because it means the treatment approach needs to address the underlying recurrent mood disorder, not just the seasonal trigger. A patient who has SAD almost certainly has recurrent MDD or bipolar disorder — and their treatment plan should reflect that.

In terms of prevalence: approximately 4–6% of the U.S. population meets full criteria for SAD. Another 10–20% experience subsyndromal seasonal mood changes — the “winter blues” that don't meet full MDD criteria but significantly impair functioning and quality of life. Geographic latitude is a strong predictor: SAD is approximately seven times more common in Alaska than in Florida.

The most robust explanatory model for winter SAD is the phase delay hypothesis. In people with SAD, the circadian clock — which is entrained primarily by light — runs delayed relative to the sleep-wake cycle. The suprachiasmatic nucleus (SCN), the brain's master circadian pacemaker, requires sufficient morning light input to properly time its signal. In winter, reduced daylight intensity and later sunrise times fail to provide adequate entrainment, and the clock drifts later. The result is that the biological morning doesn't align with the social clock — the person wakes into biological night, which produces the fatigue, hypersomnia, and cognitive sluggishness characteristic of SAD.

Two additional mechanisms compound this:

• Melatonin overproduction — the pineal gland secretes melatonin in response to darkness. In winter's longer nights and dimmer days, melatonin production extends into waking hours, amplifying the biological night signal and contributing to fatigue, hypersomnia, and the withdrawal behavior that characterizes SAD.
• Serotonin transporter upregulation — PET imaging studies have found significantly higher serotonin transporter (SERT) density in people with SAD during winter months. Higher SERT density means more rapid serotonin reuptake and lower synaptic serotonin availability — the same mechanism that SSRIs reverse. This provides a biological rationale for both the serotonin-specific symptoms of SAD (carbohydrate craving as a serotonin-precursor self-medication attempt, mood dysregulation) and the efficacy of SSRIs in treating it.

Most patients (and many providers) don't know that SAD has a summer subtype — sometimes called “reverse SAD” — that accounts for approximately 10% of SAD cases. Summer SAD presents with a completely different symptom profile from winter SAD:

• Insomnia rather than hypersomnia
• Decreased appetite and weight loss rather than carbohydrate craving and weight gain
• Agitation and irritability rather than fatigue and withdrawal
• Anxiety as a prominent feature

The proposed mechanisms are different as well: heat intolerance, excess light disrupting sleep, and possibly serotonin-mediated dysregulation in the opposite direction. Summer SAD responds to different interventions — cooler environments, dark therapy, and standard antidepressants rather than light therapy.

Summer SAD is frequently missed because clinicians operate with the heuristic that “seasonal depression” means “winter.” When a patient presents with depression in July, the seasonal pattern is rarely the first framework the provider reaches for. This diagnostic gap means patients often go years without the correct conceptualization — and without the correct treatment.

Light therapy is the best-evidenced first-line intervention for winter SAD, with response rates comparable to antidepressants in head-to-head trials. The protocol matters:

• 10,000 lux — this is the standard therapeutic intensity. Standard indoor lighting is typically 200–500 lux — meaningfully below the therapeutic threshold.
• 20–30 minutes per session, not longer. Duration beyond 30 minutes has not been shown to improve outcomes and may worsen sleep if done incorrectly.
• Morning use — ideally within 30 minutes of waking. Evening use can worsen the circadian phase delay rather than correct it and may disrupt sleep onset.
• Start before symptom onset — early fall (September–October for most patients) rather than waiting for depressive symptoms to appear. Light therapy is more effective as prevention than as acute treatment.
• Response in 1–2 weeks — significantly faster than antidepressant response. If there is no meaningful improvement by two weeks, the protocol should be reevaluated (timing, intensity, device quality) or augmented.

UV-filtering is important — UV light is not the therapeutic component and can damage eyes. The light must enter through the eyes, not the skin. Patients should keep their eyes open and directed toward (but not staring at) the light box.

Side effects are generally mild — headache, eye strain, irritability, and — particularly relevant in bipolar patients — risk of triggering hypomania or mania. Patients with bipolar disorder should use light therapy under close monitoring and at lower starting durations.

Bupropion XL: The Only FDA-Approved SAD Pharmacotherapy

Bupropion XL (extended-release) is the only medication with FDA approval specifically for the prevention of seasonal MDD episodes. The evidence base comes from randomized controlled trials showing that bupropion XL initiated before symptom onset in fall significantly reduces the incidence of SAD episodes compared to placebo.

The protocol: start in fall (typically October, or earlier for patients whose symptoms begin in September), continue through the spring, then taper when the seasonal risk window has passed. The preventive mechanism likely involves bupropion's dopaminergic and noradrenergic activity supporting the circadian and motivational deficits that characterize SAD, with some serotonergic contributions as well.

Bupropion has practical advantages for the SAD population: it does not cause weight gain (often opposite — mild weight loss), does not cause sexual dysfunction, and has activating properties that directly counter the hypersomnia and lethargy of winter SAD. Its primary cautions are seizure risk (particularly relevant at higher doses), and it is contraindicated in eating disorder patients and those with known seizure disorders.

SSRIs for Acute SAD Episodes

When light therapy alone is insufficient, SSRIs are the standard augmentation strategy and are effective for acute SAD episodes once they have developed. Sertraline and fluoxetine have the strongest evidence base for SAD, though all SSRIs are likely comparably effective given the SERT-upregulation mechanism. The same 4–6 week timeline for SSRI response applies here.

A clinical consideration: SSRIs often need to be started in September or October to reach therapeutic effect by the time symptoms typically peak in December–January. Starting in November when the patient is already in a full depressive episode means waiting 4–6 weeks for medication response during the most difficult part of the year.

Dawn Simulation

Dawn simulation — gradually brightening light beginning before waking, mimicking sunrise — is a useful adjunct to standard light therapy. Devices that increase light from darkness to bright over 30–90 minutes align waking more closely with biological dawn, which reduces sleep inertia and may improve circadian entrainment. The evidence is less robust than for 10,000 lux bright light therapy, but it is well tolerated and has no significant side effects.

Vitamin D deficiency is prevalent in geographic regions with high SAD rates, and vitamin D levels correlate with mood — which has led to widespread popular belief that vitamin D supplementation treats SAD. The clinical reality is more nuanced.

The correlation between vitamin D deficiency and depression is well-established. The causal claim — that supplementation improves SAD specifically — is not. Randomized controlled trials of vitamin D supplementation for SAD have produced mixed results, and the larger meta-analyses of vitamin D for depression generally show modest effects confined to people who are actually deficient.

My clinical practice: I check vitamin D levels in patients with SAD. If they are deficient, I recommend supplementation — not as a SAD treatment, but because correcting a vitamin D deficiency is appropriate regardless, and some patients do report mood benefit. I do not recommend high-dose supplementation in patients with normal vitamin D levels as a SAD treatment, because the evidence doesn't support it.

SAD produces recognizable cognitive patterns that are worth naming explicitly — both because they are distressing and because identifying them as symptoms rather than truths can interrupt their momentum.

The hibernation pull is the cognitive-behavioral complex that feels like a genuine need to withdraw, cancel plans, stop exercising, sleep more, and reduce all activity. The brain rationalizes this with plausible stories: “I need rest,” “I'm an introvert in winter,” “It's dark and cold, staying in is sensible.” The problem is that behavioral activation — even when motivation is low — is one of the most effective interventions for depression, and the hibernation pull moves in exactly the opposite direction.

Future catastrophizing in fall is the cognitive pattern of anticipating the coming months as inevitable suffering. When October arrives and the patient feels the first dip, the mind races forward: “Here it comes again — six months of this.” This anticipatory catastrophizing is itself depressogenic and can significantly amplify the mood impact of the initial seasonal cue. Recognizing it as a cognitive symptom of SAD — rather than accurate weather forecasting — is part of the treatment.

Documenting and communicating a seasonal pattern is one of the most important things a patient can do to ensure appropriate treatment. In a 15-minute appointment, providers often don't ask about year-round patterns — they assess current symptoms and adjust accordingly. Here are productive ways to frame the conversation:

• “I've noticed my depression follows a clear seasonal pattern. Every year starting around October, I get significantly more fatigued, I sleep more, I withdraw from people, and I have carbohydrate cravings I don't have other times of year. It lifts pretty reliably by March or April. This has happened for at least three or four years in a row.”
• “I've read about light therapy as a first-line treatment for SAD. I'm wondering whether that's appropriate for my situation and what a proper light therapy protocol looks like.”
• “I've read that bupropion XL is FDA-approved specifically for preventing seasonal MDD. I'm not currently on any medication and I'm wondering if preventive treatment makes sense given my pattern — especially since starting medication reactively in November means waiting 4–6 weeks for response during my worst months.”
• “Is it worth checking my vitamin D level? I know the evidence for supplementation is mixed for SAD specifically, but I want to make sure I'm not dealing with a deficiency on top of everything else.”